Mar 06, 2025 7:00 am EST MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Feb 20, 2025 7:00 am EST MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
Feb 04, 2025 7:00 am EST MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Jan 30, 2025 7:00 am EST MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder
Dec 16, 2024 7:00 am EST MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)
Dec 11, 2024 7:00 am EST MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress
Dec 05, 2024 7:00 am EST MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)